Want to see EVFM full AI Analyst Report?
EVFM Stock Chart & Stats
$0.01
<$0.01(13.89%)
At close: 4:00 PM EDT
$0.01
<$0.01(13.89%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume198.22K
Average Volume (3M)479.42K
Market Cap
$1.02M
Enterprise Value$60.16
Total Cash (Recent Filing)$285.00K
Total Debt (Recent Filing)$68.50M
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding132,530,080
10 Day Avg. Volume708,277
30 Day Avg. Volume479,419
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-0.02
Price to Sales (P/S)0.06
P/FCF Ratio-0.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.5
Revenue Forecast (FY)$241.13M
Bulls Say, Bears Say
Bulls Say
Strong Product Gross MarginA gross margin near 71% indicates the marketed product can generate substantial contribution after production costs. If demand and reimbursement stabilize, this product-level economics may support future operating leverage, even though current expenses remain too high.
Improving Cash BurnThe sharp reduction in operating cash outflow suggests prior cost controls or operating changes have improved financial discipline. Reaching sustained cash-flow breakeven could extend liquidity and reduce dependence on additional financing, despite current modest cash usage.
Focused Women’s Health PlatformA focused women’s health strategy and non-hormonal product positioning address specific reproductive and sexual-health needs. This specialization may support targeted commercialization and product expansion, although success remains dependent on prescription adoption and reimbursement.
Bears Say
Declining Revenue And LossesFalling revenue alongside sharply negative profitability indicates that demand, commercialization efficiency, or the cost structure is not yet supporting a sustainable operating model. Continued weakness could limit reinvestment and increase reliance on external capital.
Negative Equity And High LeveragePersistently negative equity and sizable debt relative to approximately $7.5M of assets materially weaken solvency and financial flexibility. The capital structure raises refinancing and creditor-dependence risks, potentially constraining investment in commercialization.
Restrictive High-Cost FinancingThe subordinated note increases financing expense and imposes restrictions on mergers, asset sales, liquidation, bankruptcy actions, and material business changes. These terms can constrain strategic flexibility and intensify liquidity risk if performance remains weak.
Evofem Biosciences News
EVFM FAQ
What was Evofem Biosciences’s price range in the past 12 months?
Evofem Biosciences lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Evofem Biosciences’s market cap?
Evofem Biosciences’s market cap is $1.02M.
When is Evofem Biosciences’s upcoming earnings report date?
Evofem Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 66 days.
How were Evofem Biosciences’s earnings last quarter?
Evofem Biosciences released its earnings results on Aug 19, 2026. The company reported -$0.081 earnings per share for the quarter.
Is Evofem Biosciences overvalued?
According to Wall Street analysts Evofem Biosciences’s price is currently Overvalued.
Does Evofem Biosciences pay dividends?
Evofem Biosciences does not currently pay dividends.
What is Evofem Biosciences’s EPS estimate?
Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evofem Biosciences have?
Evofem Biosciences has 132,530,080 shares outstanding.
What happened to Evofem Biosciences’s price movement after its last earnings report?
Evofem Biosciences reported an EPS of -$0.081 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evofem Biosciences?
Currently, no hedge funds are holding shares in EVFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evofem Biosciences
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.